Physician profile
Amy Marie Epling
NPI 1861010019
$9,051.41
in general payments reported to CMS, 2019-2025
37 companies · $1,994 in 2025
The $1,994 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $278 · 2022: $2,101 · 2023: $2,226 · 2024: $2,453 · 2025: $1,994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,672.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,565.85 | 2021-2025 | |
| Novo Nordisk INC | $1,384.93 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,126.38 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $787.57 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $569.12 | 2022-2025 | Rexulti |
| Pfizer INC. | $551.55 | 2021-2025 | |
| Axsome Therapeutics, INC. | $455.18 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Bayer Healthcare Pharmaceuticals INC. | $273.60 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $221.01 | 2022-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $220.82 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $195.33 | 2021-2023 | Trintellix |
| Lilly USA, LLC | $183.83 | 2021-2023 | Lyumjev, Jardiance, Baqsimi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.53 | 2022-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company Ltd. | $179.17 | 2022 | |
| Merck Sharp & Dohme LLC | $158.99 | 2022-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $152.60 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $128.47 | 2021-2025 | Repatha, Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $87.70 | 2024-2025 | Voquezna |
| Antares Pharma, INC. | $69.23 | 2021-2025 | Xyosted |
| Lundbeck LLC | $67.22 | 2024-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $59.89 | 2023-2024 | Gvoke Hypopen |
| Dexcom, INC. | $58.64 | 2021-2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $58.01 | 2022-2023 | Quviviq |
| Adlon Therapeutics L.P. | $49.55 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $36.34 | 2025 | Eliquis |
| Shield Therapeutics INC | $29.12 | 2024 | |
| Tonix Medicines, INC. | $29.08 | 2025 | Tonmya |
| Abbott Laboratories | $23.42 | 2024 | Freestyle Libre 3 |
| Alkermes, INC. | $21.27 | 2023 | Lybalvi |
| Sumitomo Pharma America, INC. | $21.06 | 2023 | Gemtesa |
| Ardelyx, INC. | $20.79 | 2025 | Ibsrela |
| Amarin Pharma, INC. | $18.75 | 2022 | |
| Sanofi Pasteur INC. | $14.12 | 2023 | |
| Vanda Pharmaceuticals INC. | $13.72 | 2025 | Hetlioz, Fanapt |
| Tolmar, INC. | $13.31 | 2024 | |
| Clarus Therapeutics INC. | $11.21 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Epling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.